Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically driven forms of excess weight.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Lilly made $1.26 billion from Zepbound sales in the third quarter, around $500 million lower than analyst forecasts, before the comparative data with Wegovy was reported. GlobalData recently ...

Lilly's move comes as Zepbound seems to be building momentum in the market – with second-quarter sales of $1.2 billion, way ahead of forecasts – at the same time as Novo Nordisk has reported ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

red down pointing triangle & Co. Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.

Manhattan apartment sales jumped 29% in the first quarter from the same period a year ago, as the wealthy sought refuge from volatile stocks to buy real estate, according to new reports.

Wegovy and Zepbound both cost roughly $1,000 before insurance and other rebates. Allowing Medicare to cover those drugs and other weight loss medications could cost $35 billion over nine years ...